Insmed Incorporated
 
公司簡況
財務
派息紀錄
盈利預測
股權變動
ETF簡況
 
 
 
公司概覽
業務類別 Biotechnology
業務概覽 Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from theUnited States from the sale of its commercial products.
公司地址 700 US Highway 202/206, Bridgewater, NJ, USA, 08807
電話號碼 +1 908 977-9900
傳真號碼 --
公司網頁 https://www.insmed.com
員工數量 1664
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Ms. S. Nicole Schaeffer Chief People Strategy Officer -- 01/04/2026
Mr. William H. Lewis, J.D.,M.B.A. Chairman of the Board, President and Chief Executive Officer 美元 854.55K 01/04/2026
Ms. Sara M. Bonstein Chief Financial Officer and Principal Accounting Officer 美元 583.19K 01/04/2026
Mr. Roger Adsett Chief Operating Officer 美元 622.59K 01/04/2026
Dr. Martina Flammer, M.B.A. Chief Medical Officer 美元 634.19K 01/04/2026
Mr. Michael A. Smith Chief Legal Officer 美元 595.27K 01/04/2026
 
董事會成員
董事會 職務 更新日期
Ms. Carol A. Schafer Independent Director 01/04/2026
Mr. David W.J. McGirr, M.B.A. Independent Director 19/02/2026
Dr. Melvin Sharoky,M.D. Independent Director 01/04/2026
Mr. David R. Brennan Lead Independent Director 01/04/2026
Mr. William H. Lewis, J.D.,M.B.A. Chairman of the Board, President and Chief Executive Officer 01/04/2026
Dr. Clarissa Desjardins, PhD Independent Director 01/04/2026
Mr. Leo Lee Independent Director 01/04/2026
Ms. Elizabeth McKee Anderson, M.B.A. Independent Director 01/04/2026
 
所屬ETF (更新日期: 02/05/2026 03:41)
代號 名稱 佔比% ▼ 持有日期
BKIVBNY Mellon Innovators ETF<0.000001%16/09/2025
BKMCBNY Mellon US Mid Cap Core Equity ETF<0.000001%06/11/2025
BMEZBlackRock Health Sciences Term Trust<0.000001%31/12/2025
BTALAGF U.S. Market Neutral Anti-Beta<0.000001%01/12/2025
CGGRCapital Group Growth ETF<0.000001%31/01/2026
CLSEConvergence Long/Short Equity ETF<0.000001%31/10/2025
ESMLiShares ESG Aware MSCI USA Small-Cap ETF<0.000001%04/03/2026
FBCGFidelity Blue Chip Growth ETF<0.000001%31/01/2026
FCUSPinnacle Focused Opportunities ETF<0.000001%08/01/2026
FDIFFidelity Disruptors ETF<0.000001%02/03/2026
FEACFidelity Enhanced U.S. All-Cap Eq ETF<0.000001%29/04/2026
FFTYCapForce IBD® 50 ETF<0.000001%15/12/2025
FMTMMarketDesk Focused U.S. Momentum ETF<0.000001%26/11/2025
FNXFirst Trust Mid Cap Core AlphaDEX® ETF<0.000001%07/10/2025
FNYFirst Trust Mid Cap Growth AlphaDEX® ETF<0.000001%07/10/2025
FSMDFidelity Small-Mid Multifactor ETF<0.000001%15/08/2025
FTKIFirst Trust Small Cp BuyWrt Inc ETF<0.000001%11/03/2026
FTXHFirst Trust Nasdaq Pharmaceuticals ETF<0.000001%22/03/2026
GSGOGoldman Sachs Growth Opportunities ETF<0.000001%06/03/2026
GTPEGoldman Sachs MSCI Wld Priv Eq RtTrkrETF<0.000001%25/11/2025
  1    2    3    4    5    6    7    8    9    10   11    12    13  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.